A Randomized, Active Comparator-Controlled, Parallel-Group, Single-Blind, Multicenter, Phase III Study to Evaluate the Efficacy, Safety and Immunogenicity of Subcutaneous Eporon Versus Epoetin Alfa (Eprex) in the Treatment of Anemia Associated With Chronic Renal Failure in Pre-dialysis Patients
Phase of Trial: Phase III
Latest Information Update: 16 Jul 2018
Price : $35 *
At a glance
- Drugs Recombinant erythropoietin (Primary) ; Epoetin alfa
- Indications Anaemia
- Focus Therapeutic Use
- Sponsors Dong-A ST
- 08 Jul 2018 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 08 Jul 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Jun 2019.
- 15 May 2018 New trial record